Last reviewed · How we verify
NCT06756321
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
EARLY_PHASE1 trial testing anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells in Relapsed/refractory Lymphoma in 9 participants. Currently enrolling.
18 March 2025
Quick facts
| Lead sponsor | Affiliated Hospital of Nantong University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 18 September 2023 |
| Primary completion | 18 March 2025 |
| Estimated completion | 18 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- Relapsed/refractory Lymphoma — all drugs for Relapsed/refractory Lymphoma →
- Relapsed/Refractory Leukemia — all drugs for Relapsed/Refractory Leukemia →
Sponsor
Affiliated Hospital of Nantong University
Who can join
Adults 18 to 70, any sex, with Relapsed/refractory Lymphoma or Relapsed/Refractory Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma.
Huang Y, Gong Y, Liu X, Ruan H, et al · · 2025 · PMID 40406106 · DOI 10.3389/fimmu.2025.1567149
Verify or expand the search:
- PubMed search for NCT06756321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Affiliated Hospital of Nantong University trials
Trials by the same sponsor.
- NCT07506668 — RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas · Phase 1, PHASE2 · not yet recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07382453 — Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases · Phase 2 · not yet recruiting
- NCT07247838 — Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke · recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06756321 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Nantong University
- Last refreshed: 3 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06756321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing